A Phase 3 interventional study of Esomeprazole and Placebo in Gastric Ulcer, Duodenal Ulcer and Rheumatoid Arthritis, sponsored by AstraZeneca. Completed at 39 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2010-05-28.
Sponsored by AstraZeneca · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing esomeprazole in Stomach Ulcer — none open to participants now, none under way, none of them phase 3. Esomeprazole · Stomach Ulcer.
Among the 11 studies testing esomeprazole in Stomach Ulcer, this one is the 9th largest by enrollment, is one of 3 that started in 2007, is one of 9 in phase 3, and was the 4th registered.
116 studies on the registry are indexed under Stomach Ulcer; 13 are open to participants now.
Browse Stomach Ulcer studies →None of the 11 studies testing esomeprazole in Stomach Ulcer is open now. The open studies under Stomach Ulcer, anywhere →
Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 10 Stomach Ulcer studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 343 is above the median of 298 across 88 interventional studies indexed under Stomach Ulcer.
Median enrollment 400 across the 11 interventional studies. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 2 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
17 studies in Stomach Ulcer by AstraZeneca: none open now, none under way, none of them phase 3. Of 17 finished, 7 (41%) have results posted.
Among the 17 studies in Stomach Ulcer by AstraZeneca, this one is the 9th largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2007, is one of 11 in phase 3, and was the 4th registered.
AstraZeneca’s Stomach Ulcer studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing esomeprazole in Stomach Ulcer, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 17 in Stomach Ulcer:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy of esomeprazole (D961H) 20 mg versus placebo once daily for up to 24 weeks of treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily nonsteroidal anti-inflammatory drug (NSAID) therapy by evaluating presence or absence of gastric and/or duodenal ulcers throughout the treatment period (24 weeks) in terms of efficacy on prevention of gastric and/or duodenal ulcers
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Placebo
Drug: Placebo
Esomeprazole 20 mg
Drug: Esomeprazole
20mg once daily oral
Also known as: Nexium
once daily oral
Absence of Gastric and/or Duodenal Ulcer Throughout the Treatment Period
The absence of gastric and/or duodenal ulcer throughout the treatment period
Time frame: each visit up to 24 weeks
Absence of Gastric and/or Duodenal Ulcer up to 4 Weeks After Treatment
The absence of gastric and/or duodenal ulcer up to 4 weeks after treatment
Time frame: up to 4 weeks
Absence of Gastric and/or Duodenal Ulcer up to 12 Weeks After Treatment
The absence of gastric and/or duodenal ulcer up to 12 weeks after treatment
Time frame: up to 12 weeks
343 randomised participants 341 in Full Analysis set and safety analysis set. Full set used for summaries of baseline char. and efficacy variables. Safety set used for summaries of safety variables. 2 excluded, took no investigational drug or had protocol deviation. 173 Esomeprazole 20 and 168 placebo had baseline information and were summarised.
| Milestone | Experimental: Esomeprazole 20 mg | Comparater: Placebo |
|---|---|---|
| Started | 175 | 168 |
| Completed | 134 | 90 |
| Not completed | 41 | 78 |
| Withdrew: Adverse event | 18 | 17 |
| Withdrew: Withdrawal by subject | 7 | 3 |
| Withdrew: Protocol violation | 8 | 1 |
| Withdrew: Recurrence of gastric ulcer | 8 | 57 |
The absence of gastric and/or duodenal ulcer throughout the treatment period
| Participants | Experimental: Esomeprazole 20 mg | Comparater: Placebo |
|---|---|---|
| Absence of Gastric and/or Duodenal Ulcer Throughout the Treatment Period | 167 | 112 |
The absence of gastric and/or duodenal ulcer up to 4 weeks after treatment
| Participants | Experimental: Esomeprazole 20 mg | Comparater: Placebo |
|---|---|---|
| Absence of Gastric and/or Duodenal Ulcer up to 4 Weeks After Treatment | 172 | 133 |
The absence of gastric and/or duodenal ulcer up to 12 weeks after treatment
| Participants | Experimental: Esomeprazole 20 mg | Comparater: Placebo |
|---|---|---|
| Absence of Gastric and/or Duodenal Ulcer up to 12 Weeks After Treatment | 168 | 119 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental: Esomeprazole 20 mg | — | 12/173 (6.9%) | 134/173 (77.5%) |
| Comparater: Placebo | — | 5/168 (3%) | 124/168 (73.8%) |
| Event | Experimental: Esomeprazole 20 mg | Comparater: Placebo |
|---|---|---|
| Faeces DiscolouredGastrointestinal disorders | 0/173 | 1/168 |
| Upper Gastrointestinal HaemorrhageGastrointestinal disorders | 0/173 | 1/168 |
| Gastroduodenal HaemorrhageGastrointestinal disorders | 0/173 | 1/168 |
| Pneumonia BacterialInfections and infestations | 0/173 | 1/168 |
| Gastric CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/173 | 1/168 |
| Oesophageal CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/173 | 1/168 |
| Haemorrhagic AnaemiaBlood and lymphatic system disorders | 0/173 | 1/168 |
| Colonic PolypGastrointestinal disorders | 1/173 | 0/168 |
| EnterocolitisGastrointestinal disorders | 1/173 | 0/168 |
| VomitingGastrointestinal disorders | 1/173 | 0/168 |
| Event | Experimental: Esomeprazole 20 mg | Comparater: Placebo |
|---|---|---|
| NasopharyngitisInfections and infestations | 27/173 | 27/168 |
| Abdominal Pain UpperGastrointestinal disorders | 18/173 | 22/168 |
| Stomach DiscomfortGastrointestinal disorders | 15/173 | 17/168 |
| Abdominal DistensionGastrointestinal disorders | 15/173 | 11/168 |
| Reflux OesophagitisGastrointestinal disorders | 10/173 | 13/168 |
| NauseaGastrointestinal disorders | 11/173 | 9/168 |
| AnorexiaMetabolism and nutrition disorders | 11/173 | 6/168 |
| DyspepsiaGastrointestinal disorders | 7/173 | 10/168 |
| DiarrhoeaGastrointestinal disorders | 9/173 | 6/168 |
| ConstipationGastrointestinal disorders | 7/173 | 5/168 |
| Age, Customized(participants) | Experimental: Esomeprazole 20 mg | Comparater: Placebo | Total |
|---|---|---|---|
| <65 years | 78 | 91 | 169 |
| Between 65 and 74 years | 59 | 54 | 113 |
| >=75 years | 36 | 23 | 59 |
| Missing | 2 | 0 | 2 |
| Sex/Gender, Customized(participants) | Experimental: Esomeprazole 20 mg | Comparater: Placebo | Total |
|---|---|---|---|
| Female | 108 | 100 | 208 |
| Male | 65 | 68 | 133 |
| Missing | 2 | 0 | 2 |
The record gives a start of Aug 2007 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esomeprazole